Návratnosť imania spoločnosti Aerie Pharmaceuticals Inc
Aká je hodnota metriky Návratnosť imania spoločnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Návratnosť imania spoločnosti Aerie Pharmaceuticals Inc je 32.63%
Aká je definícia metriky Návratnosť imania?
Návratnosť imania (Return on equity - ROE) je rentabilita vlastného imania. Vypočíta sa vydelením čistého príjmu za fiškálny rok vlastným imaním.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Návratnosť imania spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Aerie Pharmaceuticals Inc
Čomu sa venuje spoločnosť Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou návratnosť imania podobnou spoločnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Návratnosť imania spoločnosti Accenture plc je 32.59%
- Hodnota metriky Návratnosť imania spoločnosti Denbury je 32.60%
- Hodnota metriky Návratnosť imania spoločnosti Synalloy je 32.61%
- Hodnota metriky Návratnosť imania spoločnosti Check Point Software Technologies je 32.61%
- Hodnota metriky Návratnosť imania spoločnosti China Ceramics Co je 32.61%
- Hodnota metriky Návratnosť imania spoločnosti Southern Copper je 32.62%
- Hodnota metriky Návratnosť imania spoločnosti Aerie Pharmaceuticals Inc je 32.63%
- Hodnota metriky Návratnosť imania spoločnosti 1137943 je 32.64%
- Hodnota metriky Návratnosť imania spoločnosti Arena REIT je 32.65%
- Hodnota metriky Návratnosť imania spoločnosti Emcor je 32.67%
- Hodnota metriky Návratnosť imania spoločnosti Pzena Investment Management Inc je 32.68%
- Hodnota metriky Návratnosť imania spoločnosti Établissements Maurel & Prom SA je 32.71%
- Hodnota metriky Návratnosť imania spoločnosti Altisource Portfolio Solutions S.A je 32.72%